Elanco Animal Health (ELAN) EBIAT (2017 - 2026)

Elanco Animal Health has disclosed EBIAT across 10 years of filings, most recently posting $57.0 million for Q1 2026.

• EBIAT for Q1 2026 came in at $57.0 million, down 14.93% year-over-year; the trailing twelve-month figure through Mar 2026 was -$242.0 million (down 164.88% YoY), and the FY2025 annual result was -$232.0 million, down 168.64% from the prior year.
• EBIAT came in at $57.0 million for Q1 2026 at Elanco Animal Health, up from -$276.0 million in the prior quarter.
• In the past five years, EBIAT ranged from a high of $364.0 million in Q3 2024 to a low of -$1.1 billion in Q3 2023.
• The 5-year median for EBIAT is -$10.0 million (2022), against an average of -$67.4 million.
• Across the five-year window, EBIAT surged 179.69% in 2022 and sank 3350.0% in 2025, its largest moves.
• Elanco Animal Health's EBIAT stood at -$54.0 million in 2022, then slumped by 161.11% to -$141.0 million in 2023, then jumped by 94.33% to -$8.0 million in 2024, then tumbled by 3350.0% to -$276.0 million in 2025, then surged by 120.65% to $57.0 million in 2026.
• The last three EBIAT figures came in at $57.0 million (Q1 2026), -$276.0 million (Q4 2025), and -$34.0 million (Q3 2025), per Business Quant data.